Lenvatinib (off Label)
Lenvatinib MSK Phase 2
Eisai (investigator studies) · Phase 2 · Active, not recruiting · Enrollment 33
| Arm | Reported safety |
|---|---|
| Lenvatinib 24 mg | grade 3 or 4 hypertension: 28.1%, primary analysisdiscontinued for drug-related issues: 18 patients (of 32), primary analysis |
A count stays a count. This page does not turn a count into a percent.